Arterial hypertension after orthotopic cardiac transplantation  by Frohlich, Edward D. et al.
1102 
JACC Vol. 153 No. S 
April WXk? :02-3 
As we enter the decade of the 191;Os, cardiac traasplanlation 
has become an accepted form of therapy for selected pa- 
tients with end-st cardiac disease. This once dramatic 
therapeutic interv on has achieved broad clinical imple- 
mntatiors not because: OF the implied surgical expertise 
necessary for its use, but because of improvements in the 
osis and management of infections, the use of routine 
iac biopsy and, not least, the remarkable advances in 
our understanding of the immune response to tissue trans- 
plantation and the associated advances in immunosupprss- 
e and corticosteroids 
lion of eyclosporinc, remarkable ~mpr~~v~~~ents in tissue 
donor acceptance attd rejection ~~~~no~~~na permitted in- 
creased survival rates in cardiac (and other o 
0wilvcr, as with most s in lithe, there is a down 
ppressive therapy; of partic- 
~l~vun~~ are the associated complications of arterial 
on and chronic renal insuffi&ncy. Despite the use 
on associated with 
orthotopic cardiac 
I-far greater than 
Elsewhere in this Journal, Farge et al. 
(21 report their extensive experience with systemic hyper- 
tension and associated renal dysfunction and left ventricular 
h~~~~phy in 8s of I I2 patients undergoing cardiac tmns- 
Fm the Alton Ochsner kdiial Foun&tion. New Orleans, Louisiana. 
: Edward D. Frwhlich. MD. Vice President for 
k&mic Affairs. Alton Ochsner Medical Foundation, 1516 Jefferson High- 
way. New Orleans. Louisiana 70121. 
plantation who received “triple drug” low dosage 
suppressive therapy. Their finding of hyperteosio~ i 
these patients after approximately 1 year is consistent with 
previous reports, and 71% of these patients developed new 
hypertension. Their report from N&pitai Broussais in Paris is 
important for onde~s~o~n~ this ex~grien~~ 
details concerning the n 
other diseases, the pree 
the related ~athophysio~o 
we do know, however, 
related to coronary heart disease and hy 
increased prior to and associ~t~d witb 
mcnt. 
mortality rates associated with 
which have been welt described; 
effects and the patho~hysio~ 
t~nsplantatio~ hypertension 
report bh Farge ct at. (2) st 
essential hyp~~ensive ~~banisms, althou 
are not the same as those in p 
hypertension. 
mechanism and active a is the likely 
systemic hem~ynami~ alteration. However. volume factors 
may participate if lean boast mass is reduce 
nded secondary to tbc administration of s 
over, Krause the p~va~~~~e of erte~sion is increased in 
al1 patients receiving cyctospor it likely plays a role in 
producing increased contractility of arteriolar smooth mus- 
cle. 
In this regard. cyclosporine has been demonstrated to 
promote renal and systemic arteriolar constriction in kidney 
(41 and heart (5) transplant recipients. Among the postulated 
mechanisms for this effect are increased thromboxane pro- 
duction (61, diminished production of prostacyclin and acti- 
vation of the renin-angioteasin system (7) and augmented 
adrenergic activity (8). Electrolytic disturbances such as 
hypomagnesemia have been suggested (9). Arguments 
against some of these hypotheses in cardiac transplant 
recipients with hypertension are low plasma renin activity 
(IO) and normal circulating norepinephrine levels (3). How- 
ever. activation of local tissue renin-angiotensin systems in 
the arterio!es and the heart (I 1,121 and local olatio~ of 
adrenergic function (121, or induction of local autocrinel 
paracrine humoral substances or tissue growth factors re- 
mind US not to exclude these mechanisms in the pathogene. 
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